
News &
Media
-
Neurotech International (ASX: NTI) – Webinar Presentation
Dr. Alexandra Andrews – CEO – Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of its proprietary cannabis strains.
-
Webinar Recap – NTI, MHK, RPM & ESK
View More -
Australia’s top 20 cannabis companies
A report from FreshLeaf Analytics forecasts Australian medicinal cannabis sales of $423 million for 2022, up from an estimated $230 million in 2021. As prices for practically everything rose last year, medicinal cannabis prices went down on average, opening up more budgets to treatment.
-
Neurotech International (ASX:NTI) appoints Alexandra Andrews as CEO
Dr Andrews has experience in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments.
She has a Doctor of Philosophy in Neuroscience from the University of Western Australia.
-
Neurotech International Phase I/II Autism Results Due this Quarter
In July last year Neurotech International (NTI: $0.05) acquired a license from Dolce CannGroup for access to specific proprietary strains of cannabis for the potential treatment of various neurological conditions.
-
Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans
View More -
From Backstreet to Highstreet: How Cannabis Has Entered the Mainstream
Explore the $31.96 billion global cannabis market that is disrupting the healthcare and pharmaceutical industries.
-
Australia’s Neurotech Inks Cannabis Cultivation Partnership
Neurotech International Limited (ASX:NTI) has established a strategic medical cannabis cultivation partnership with CannaPacific Limited.
-
Neurotech just started world’s first THC-less cannabis study in autistic children
The Phase I/II clinical trial announced today is a groundbreaking study where medicinal cannabis containing little to no THC is being tested on autistic children.